GlassScriptPhysician profile
Emily Weston
NPI 1366098881
$3,316.68
in general payments reported to CMS, 2019-2025
29 companies · $393 in 2025
The $393 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $69.80 · 2022: $1,197 · 2023: $1,065 · 2024: $592 · 2025: $393.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,050.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,049.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $645.92 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $355.84 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Amgen INC. | $246.51 | 2022-2025 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $232.44 | 2022-2025 | Mounjaro, Jardiance, Kisunla |
| Pfizer INC. | $211.24 | 2022-2025 | |
| Abbvie INC. | $207.15 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $153.11 | 2022-2025 | Farxiga, Airsupra, Breztri |
| Otsuka America Pharmaceutical, INC. | $150.60 | 2022-2024 | Rexulti |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $150.60 | 2021-2024 | Xifaxan |
| Phathom Pharmaceuticals, INC. | $98.81 | 2024-2025 | Voquezna |
| Boehringer Ingelheim Pharmaceuticals, INC. | $91.56 | 2022-2024 | Jardiance, Tradjenta |
| Exact Sciences Corporation | $72.08 | 2023-2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $70.69 | 2022-2023 | Xarelto |
| Dexcom, INC. | $69.20 | 2022-2025 | Dexcom G6 Transmitter |
| Organon LLC | $61.06 | 2022-2023 | Nexplanon |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $59.79 | 2025 | Ohtuvayre |
| Novartis Pharmaceuticals Corporation | $59.02 | 2022-2023 | |
| Merck Sharp & Dohme LLC | $56.52 | 2021-2023 | Belsomra, Segluromet, Steglatro |
| Biohaven Pharmaceutical Holding Company LTD. | $49.43 | 2022 | |
| Shield Therapeutics INC | $42.63 | 2023-2024 | Accrufer |
| Astellas Pharma US INC | $41.10 | 2023 | Veozah |
| Neurelis, INC. | $35.16 | 2023-2024 | Valtoco |
| Biohaven Pharmaceuticals, INC. | $30.93 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $28.96 | 2022 | |
| Ardelyx, INC. | $28.38 | 2024 | Ibsrela |
| Travere Therapeutics, INC. | $21.33 | 2025 | Filspari |
| Sanofi-Aventis U.S. LLC | $21.10 | 2022 | |
| Medtronic, INC. | $13.27 | 2024 | Minimed 780g |
| Bayer Healthcare Pharmaceuticals INC. | $12.25 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Weston listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.